APA (7th ed.) Citation

O, K., M, T., K, N., E, L., GY, H., MI, H., . . . CL, S. (2018). Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nature communications, 9(1), 3970. https://doi.org/10.1038/s41467-018-05564-z

Chicago Style (17th ed.) Citation

O, Kondrashova, et al. "Methylation of All BRCA1 Copies Predicts Response to the PARP Inhibitor Rucaparib in Ovarian Carcinoma." Nature Communications 9, no. 1 (2018): 3970. https://doi.org/10.1038/s41467-018-05564-z.

MLA (9th ed.) Citation

O, Kondrashova, et al. "Methylation of All BRCA1 Copies Predicts Response to the PARP Inhibitor Rucaparib in Ovarian Carcinoma." Nature Communications, vol. 9, no. 1, 2018, p. 3970, https://doi.org/10.1038/s41467-018-05564-z.